Emphysema-Pipeline Review, H1 2015

Emphysema-Pipeline Review, H1 2015

  • Products Id :- GMDHC6434IDB
  • |
  • Pages: 45
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Emphysema-Pipeline Review, H1 2015


Global Markets Direct's, 'Emphysema-Pipeline Review, H1 2015', provides an overview of the Emphysema's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Emphysema, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Emphysema and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides a snapshot of the global therapeutic landscape of Emphysema

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Emphysema and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Emphysema products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Emphysema pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Emphysema

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Emphysema pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Emphysema Overview 6

Therapeutics Development 7

Pipeline Products for Emphysema-Overview 7

Pipeline Products for Emphysema-Comparative Analysis 8

Emphysema-Therapeutics under Development by Companies 9

Emphysema-Pipeline Products Glance 10

Late Stage Products 10

Early Stage Products 11

Emphysema-Products under Development by Companies 12

Emphysema-Companies Involved in Therapeutics Development 13

Angion Biomedica Corp. 13

Boehringer Ingelheim GmbH 14

Intrexon Corporation 15

Protalix BioTherapeutics, Inc. 16

rEVO Biologics 17

Emphysema-Therapeutics Assessment 18

Assessment by Monotherapy Products 18

Assessment by Combination Products 19

Assessment by Target 20

Assessment by Mechanism of Action 22

Assessment by Route of Administration 24

Assessment by Molecule Type 26

Drug Profiles 28

(olodaterol + tiotropium bromide)-Drug Profile 28

Product Description 28

Mechanism of Action 28

R&D Progress 28

Alpha-1 Antitrypsin With rHuPH20-Drug Profile 31

Product Description 31

Mechanism of Action 31

R&D Progress 31

BB-3-Drug Profile 32

Product Description 32

Mechanism of Action 32

R&D Progress 32

EDO-66-Drug Profile 34

Product Description 34

Mechanism of Action 34

R&D Progress 34

Monoclonal Antibody to Inhibit EMAP II for Emphysema-Drug Profile 35

Product Description 35

Mechanism of Action 35

R&D Progress 35

PRX-107-Drug Profile 36

Product Description 36

Mechanism of Action 36

R&D Progress 36

Recombinant Human Alpha-1 Antitrypsin-Drug Profile 37

Product Description 37

Mechanism of Action 37

R&D Progress 37

TRN-101-Drug Profile 38

Product Description 38

Mechanism of Action 38

R&D Progress 38

Emphysema-Recent Pipeline Updates 39

Emphysema-Dormant Projects 42

Emphysema-Product Development Milestones 43

Featured News & Press Releases 43

Jun 20, 2013: Protalix BioTherapeutics Reveals Information For Emphysema Drug, PRX-107 43

Appendix 44

Methodology 44

Coverage 44

Secondary Research 44

Primary Research 44

Expert Panel Validation 44

Contact Us 44

Disclaimer 45

List of Tables

Number of Products under Development for Emphysema, H1 2015 7

Number of Products under Development for Emphysema-Comparative Analysis, H1 2015 8

Number of Products under Development by Companies, H1 2015 9

Comparative Analysis by Late Stage Development, H1 2015 10

Comparative Analysis by Early Stage Development, H1 2015 11

Products under Development by Companies, H1 2015 12

Emphysema-Pipeline by Angion Biomedica Corp., H1 2015 13

Emphysema-Pipeline by Boehringer Ingelheim GmbH, H1 2015 14

Emphysema-Pipeline by Intrexon Corporation, H1 2015 15

Emphysema-Pipeline by Protalix BioTherapeutics, Inc., H1 2015 16

Emphysema-Pipeline by rEVO Biologics, H1 2015 17

Assessment by Monotherapy Products, H1 2015 18

Assessment by Combination Products, H1 2015 19

Number of Products by Stage and Target, H1 2015 21

Number of Products by Stage and Mechanism of Action, H1 2015 23

Number of Products by Stage and Route of Administration, H1 2015 25

Number of Products by Stage and Molecule Type, H1 2015 27

Emphysema Therapeutics-Recent Pipeline Updates, H1 2015 39

Emphysema-Dormant Projects, H1 2015 42

List of Figures

Number of Products under Development for Emphysema, H1 2015 7

Number of Products under Development for Emphysema-Comparative Analysis, H1 2015 8

Number of Products under Development by Companies, H1 2015 9

Comparative Analysis by Early Stage Products, H1 2015 11

Assessment by Monotherapy Products, H1 2015 18

Number of Products by Top 10 Targets, H1 2015 20

Number of Products by Stage and Top 10 Targets, H1 2015 21

Number of Products by Top 10 Mechanism of Actions, H1 2015 22

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 23

Number of Products by Top 10 Routes of Administration, H1 2015 24

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 25

Number of Products by Top 10 Molecule Types, H1 2015 26

Number of Products by Stage and Top 10 Molecule Types, H1 2015 27

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com

Angion Biomedica Corp.

Boehringer Ingelheim GmbH

Intrexon Corporation

Protalix BioTherapeutics, Inc.

rEVO Biologics

Emphysema Therapeutic Products under Development, Key Players in Emphysema Therapeutics, Emphysema Pipeline Overview, Emphysema Pipeline, Emphysema Pipeline Assessment

select a license

Single User License
USD 2000 INR 132400
Site License
USD 4000 INR 264800
Corporate User License
USD 6000 INR 397200



The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...

Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@] kenresearch.com